In the United States, 3 vaccines against SARS-CoV-2 are currently available: 2 are under Emergency Use Authorization (EUA), and 1 has received approval from the FDA for its Biologics License Application (BLA). Even as the campaign to immunize the population and to improve treatment outcomes for those with COVID-19 continue, viral variants of concern have emerged that contribute to transmission, and possibly severity of outcomes, particularly among unvaccinated individuals. This series of audio podcasts provides useful updates on the available vaccines, as well as guidance on optimizing distribution and overcoming barriers to vaccination.
All content for COVID-19 Vaccine Updates is the property of Medscape and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In the United States, 3 vaccines against SARS-CoV-2 are currently available: 2 are under Emergency Use Authorization (EUA), and 1 has received approval from the FDA for its Biologics License Application (BLA). Even as the campaign to immunize the population and to improve treatment outcomes for those with COVID-19 continue, viral variants of concern have emerged that contribute to transmission, and possibly severity of outcomes, particularly among unvaccinated individuals. This series of audio podcasts provides useful updates on the available vaccines, as well as guidance on optimizing distribution and overcoming barriers to vaccination.
In the United States, 3 vaccines against SARS-CoV-2 are currently available: 2 are under Emergency Use Authorization (EUA), and 1 has received approval from the FDA for its Biologics License Application (BLA). Even as the campaign to immunize the population and to improve treatment outcomes for those with COVID-19 continue, viral variants of concern have emerged that contribute to transmission, and possibly severity of outcomes, particularly among unvaccinated individuals. This series of audio podcasts provides useful updates on the available vaccines, as well as guidance on optimizing distribution and overcoming barriers to vaccination.
